Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bullish price target.
Looking at the drug they are developing it’s either home run or nothing.
$44 price target. Lol
https://www.benzinga.com/quote/DRRX/analyst-ratings
100% agree. This will be a total loss for investors.
There is really nothing positive about a R/S in a penny stock. It always seems to get back to the pre split price and 90% of your investment is toast. $3.60 looks better but in reality only 36 cents compared to last week
1/10 RS. 100% loss incoming. Smfh!
Been not liking this company since I was told about it. They are just trying to buy time. Stick a fork in this POS.
The vote is mostly just symbolic since corporate has enough votes to pass what they want.
I have NEVER seen a stock selling for under a buck do well after a R/S....it just seems to eventually get back to the pre split price and you are minus 90% of your shares.
I also voted against it
I voted against the R/S. F them!!! Hope everyone does the same. Garbage…..
Yup....I just dumped my shares at a loss to salvage something
What a garbage company…….how do you let your share price get this low.
How low are they gonna let this POS go?! My god……Smfh.
Pretty much puts everything in a nutshell. DRRX POS~!
Will be lucky to see $2 again.....
If in this play.... get out ...... or take the ride down.
Just my opinion.
The two big catalyst for me is: (1). The authorized share count was not increased to 600,000,000 shares, even though DRRX had the votes; that is very, very, interesting. (2) The quarterly filing was was moved up to 7/29/2021. Theses two catalyst, could pertain to a partnership or a buyout news pending. The ship is getting ready to sail, and the rocket is going to the moon. My Opinion!
I see why the stock price is down; all the Insiders are Filing Form 4 today and receiving stock at a very low price.
I’ll take $3.49
WILL NOT MOVE OVER $3.5O
DRRX is going nowhere real fast. Bail and grab some $AMC.
Durect Price Target Announced at $6.00/Share by HC Wainwright & Co.
I think so. I bought a small block today and intend to sit on this for a bit.
8-K out yesterday, showing that the offering is done and closed. Anyone think this will start to rise now that the offering is over and done with?
Got 50K somewhat derisked and looking for an upside.
DURECT Corporation Announces U.S. FDA Approval of POSIMIR® For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression
https://www.marketwatch.com/press-release/durect-corporation-announces-us-fda-approval-of-posimir-for-post-surgical-pain-reduction-for-up-to-72-hours-following-arthroscopic-subacromial-decompression-2021-02-02?siteid=bigcharts&dist=bigcharts&tesla=y
Any renewed interest? Anyone?
News: $DRRX Durect Corp (DRRX) Q2 2020 Earnings Call Transcript
Image source: The Motley Fool. Durect Corp (NASDAQ: DRRX) Q2 2020 Earnings Call Aug 3, 2020 , 4:30 p.m. ET Operator Continue reading
Got this from DRRX - Durect Corp (DRRX) Q2 2020 Earnings Call Transcript
News: $DRRX DURECT Corporation Announces Second Quarter 2020 Financial Results and Update of Programs
CUPERTINO, Calif. , Aug. 3, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2020 and provided a corporate update. Total revenues were $25.8 million and net income was $14.3 million for the three ...
Read the whole news DRRX - DURECT Corporation Announces Second Quarter 2020 Financial Results and Update of Programs
* * $DRRX Video Chart 06-25-2020 * *
Link to Video - click here to watch the technical chart video
* * $DRRX Video Chart 05-12-2020 * *
Link to Video - click here to watch the technical chart video
NDA filed, when ever approved this will be $25 over night
this is looking better and better for buy in
..about due.
* * $DRRX Video Chart 02-11-2020 * *
Link to Video - click here to watch the technical chart video
I am anticipating failure from the FDA also but one never knows. Let's hope they do the right thing (but that would be unusual).
The eta was April from what I was reading. And yes, it can come sooner. If approved, and based off price action and possible increase short position, this could rocket on positive news.
I think the current pps is anticipating failure.
I’m still in, just waiting.
If this was a lock the FDA would have approved already. Should hear soon either way.
What a hell of a buying opportunity for those of you just getting involved.
BUGGY should have been BIGGY. Finger slip
Great day based on what took place yesterday. Very heavy buying to cover all the selling. We now wait for the buggy in June or July.
It would be interesting to see a comparison to Exparel. Properly used, Exparel makes the patients much more comfortable, even if they still use some narcotics.
I completely understand where you are coming from. However the opium epidemic is a huge problem. If a doctor can prescribe this right off the bat and give a pain rating of six versus eight with the competition, why would that doctor risk putting that patient in addiction phase and risk a lawsuit of malpractice?
Just my non scientific opinion... I would think POSIMIR® would need to clearly show a benefit to the patients. Enough so that it would compete against the SOC (standard of care). If it is, it would penetrate the market and make a profit. IT MAY get approved, but I'm not seeing it close in on the competition enough that surgeons would reach for it.
Like I said though, that's just my unscientific opinion.
Although the FDA considers the recommendations of the AADPAC, the recommendations by the panel are non-binding. The final decision regarding pending regulatory actions for a product is made by the FDA.
"We appreciated this opportunity to present an in depth overview of our POSIMIR data and discuss it with the committee," stated James E. Brown, President and CEO of DURECT. "We are encouraged by the support from a number of the Committee members. We continue to believe the data meets all of the regulatory requirements and that the weight of the evidence supports approval. We look forward to working with the agency as it completes its review of the POSIMIR application."
https://ih.advfn.com/stock-market/NASDAQ/durect-DRRX/stock-news/81550685/durect-corporation-announces-outcome-of-fda-adviso
Understood. Thanks.
Followers
|
69
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1025
|
Created
|
07/17/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |